GHRP-6: The Complete Guide

GHRP-6 is the original synthetic growth-hormone-releasing peptide: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, six amino acids with a C-terminal amide and two protease-resistance D-amino-acid substitutions (D-Trp at position 2, D-Phe at position 5).

Founding paper:

PMID 6714155 — Bowers CY, Momany FA, Reynolds GA, Hong A. Endocrinology 1984 May;114(5):1537-45. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.”

Family lineage:

• GHRP-6 is the parent scaffold from which GHRP-2 (pralmorelin), hexarelin, GHRP-1, and structurally related ghrelin-receptor agonists were derived.
• Pre-GHRP-6 ancestry: weak GH-releasing Met-enkephalin analogs (Momany & Bowers 1981, PMID 6109621). The final hexapeptide is not a structural enkephalin, but it traces directly back to enkephalin scaffolds via iterative conformational-energy design.
• The ghrelin receptor (GHS-R1a) was cloned in 1996 (Howard et al., Science, PMID 8688086) specifically because GHRP-6 and the small-molecule MK-677 needed a receptor.
• The natural ligand ghrelin was discovered in 1999 (Kojima et al., Nature, PMID 10604470) — after GHRP-6, after the receptor was cloned.

GHRP-6 is, in other words, the synthetic small-peptide mimetic that predicted the existence of the natural hormone — one of the few cases in pharmacology where the drug was discovered before its endogenous counterpart.

Regulatory status:

• FDA (US): not approved. No NDA, no IND, not on the 503A bulks list, not on the 503B essentially-copies list, not in Orange Book. Research chemical only in the US.
• EMA (EU): not approved.
• Japan: note that GHRP-2 (pralmorelin) — not GHRP-6 — was developed as a clinical GH-deficiency diagnostic agent in Japan. Do not write “GHRP-6 is approved in Japan”; that’s GHRP-2.
• WADA 2026: prohibited at all times under S2.2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics — GHS / GHRP sub-class), in force 2026-01-01. Banned with alexamorelin, ipamorelin, hexarelin (examorelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5.
• DEA: not scheduled.

Receptor and signaling:

• Receptor: Growth Hormone Secretagogue Receptor 1a (GHS-R1a), a class-A G-protein-coupled receptor expressed on anterior-pituitary somatotrophs, hypothalamic arcuate-nucleus neurons, ventromedial / paraventricular nuclei, and at lower density on heart, vasculature, immune cells, pancreas, and gut.
• Signaling cascade: Gαq/11 → phospholipase C → IP₃ + diacylglycerol → intracellular Ca²⁺ mobilization + PKC activation → Ca²⁺-dependent GH exocytosis (Herrington & Hille 1994, PMID 8070352).
• Distinct from GHRH-R signaling. Sermorelin / tesamorelin / CJC-1295 act on the GHRH receptor (class-B GPCR, Gαs → cAMP → PKA). GHRP-6 acts on GHS-R1a (class-A GPCR, Gαq → Ca²⁺). Because the two pathways converge through different second messengers, GHRH + GHRP synergy is robust in human acute provocation (Popovic 1994, PMID 8045963; Cordido 1996, PMID 8772550).

Three-pronged GH mechanism:

1. Direct pituitary stimulation on somatotrophs (perifused-cell preps; Badger 1984, PMID 6148232).
2. Hypothalamic mediation. GHRP-6-induced GH release is completely blocked in patients with hypothalamic-pituitary disconnection (Popovic 1995, PMID 7883854) — meaning the full in vivo GH response requires hypothalamic integrity.
3. Functional release-from-somatostatin-brake (inferred from the GHRH+GHRP synergy data).

Appetite mechanism — the GHRP-6 differentiator:

GHRP-6 binds GHS-R1a in the hypothalamic arcuate nucleus and ventromedial hypothalamus, the same loci where endogenous ghrelin acts on NPY / AgRP feeding circuits. Verified evidence:

• PMID 39813130 (Poelman et al., Endocrinology 2025): intranasal GHRP-6 activates appetite-regulating neurons in the mouse hypothalamus and increases GH levels — the most recent verified GHRP-6 primary paper.
• PMID 32224927 (Yokota-Nakagi et al., Nutrients 2020): IP GHRP-6 enhanced high-fat-diet intake in ovariectomized rats; effect reversed by estradiol.
• Antagonist literature using [D-Lys³]-GHRP-6 consistently shows that blocking GHS-R1a at hypothalamic sites reduces ghrelin-driven feeding — confirming the agonist circuit.

The defensible distinguishing feature for GHRP-6 is appetite, real and central, dose-dependent and peer-reviewed. Not "more cortisol than other GHRPs" — see the comparison section below.

This is the most consequential disambiguation point for any GHRP-6 reader. Older content circulating online frames GHRP-6 as exceptionally cortisol- and prolactin-elevating compared to GHRP-2; the head-to-head literature does not support that framing.

What the head-to-head data actually says:

PMID 9285939 (Arvat et al., Peptides 1997). Title: “Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man.” Verbatim: GHRP-2 and hexarelin are “synthetic, non-natural super-analogs of GHRP-6” with stronger GH-releasing activity than the parent GHRP-6. PRL responses across all doses of GHRP-2 or hexarelin were similar (between the two super-analogs); ACTH/cortisol-releasing activity was “similar to that of hCRH” — i.e., real and measurable, but not exceptionalist for GHRP-6.

PMID 9096259 (Cheng et al., Life Sci 1997): “GHRP-2 was found to stimulate GH release from rat pituitary cells via the same receptor and mechanism as GHRP-6.”

Corrected comparison table:

Peptide	GH Release	Cortisol / Prolactin / ACTH	Hunger / Appetite
Ipamorelin	Moderate	None at clinical doses	Minimal
GHRP-6 (parent)	Moderate–High	Yes — real, similar magnitude to other GHRPs	Highest of the older GHRPs
GHRP-2 (super-analog)	High	Yes — similar to GHRP-6 (possibly more pronounced given higher potency, PMID 9285939)	Moderate
Hexarelin (super-analog)	Highest	Yes — similar to GHRP-2	Moderate

What the literature DOES support as a GHRP-6 distinction:

1. Strongest appetite signal among the older GHRPs (PMIDs 39813130, 32224927; antagonist literature with [D-Lys³]-GHRP-6 confirms the circuit).
2. Lower GH potency per microgram — GHRP-2 and hexarelin are MORE potent on the GH side, not less.
3. Historical primacy — first GHRP synthesized; the parent of the family.

When to choose GHRP-6 vs alternatives:

• Use case: appetite is a feature (cachexia recovery, recovering from illness, hard-gainers struggling to eat enough) → GHRP-6 is the right tool.
• Use case: clean GH pulse without HPA-axis activation → Ipamorelin is the modern standard.
• Use case: maximum GH potency → GHRP-2 or Hexarelin.
• Use case: GHRH synergy → pair any GHRP with Sermorelin, CJC-1295, or Tesamorelin.

No Phase 2 / Phase 3 RCT exists for GHRP-6 as a chronic therapy. The dosing below is community / practitioner convention carried over from broader GHRP-class practice; it is not anchored to a trial-derived regimen.

Parameter	Common Range
Dose per injection	100–300 µg SC
Frequency	2–3× per day, fasted (no food / no fat for 30–60 min before or after)
Cycle length	8–16 weeks on, with breaks; tachyphylaxis emerges with continuous use (class behavior, well-documented for hexarelin)
Best dose timing	Morning (fasted), pre-/post-workout, before bed (~30 min before sleep on empty stomach)
Route	SC standard; intranasal effective per Frieboes 1999 (PMID 10336729); oral bioavailability is poor

Common stack: GHRP-6 + GHRH analog

Pairing GHRP-6 with a GHRH analog (CJC-1295 no-DAC, sermorelin, or tesamorelin) drives the synergy demonstrated in Popovic 1994 (PMID 8045963) and Cordido 1996 (PMID 8772550). The two pathways converge on the somatotroph through different second messengers, producing a larger GH pulse than either alone.

Why fasted dosing matters:

Free fatty acids (FFAs) blunt the GHRP GH response. PMID 8772549 (Peino 1996) showed that suppressing FFAs with acipimox potentiates the GHRP-6 GH response; PMID 8772550 (Cordido 1996) showed FFA suppression rescues the blunted response in obese subjects. Eating — especially fat — before injection meaningfully reduces the on-target effect.

Standard SC peptide reconstitution. For a typical 5 mg lyophilized vial:

• Add 2 mL bacteriostatic water → 2.5 mg/mL (2500 µg/mL).
• On a U-100 insulin syringe, 1 unit = 25 µg.
• So a 100 µg dose = 4 units; a 200 µg dose = 8 units; a 300 µg dose = 12 units.

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate for longer.
• Reconstituted: refrigerate. Use within 28 days.
• Sensitivity: the histidine and tryptophan residues are oxidation-sensitive (Cheng 1995, PMID 8633765). Protect from light and avoid temperature extremes.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

Common acute (verified):

• Hunger / appetite stimulation, ~20–30 min post-injection. The GHRP-6 signature. Real and central (PMID 39813130). Community user reports consistently describe a noticeable hunger surge.
• GH elevation — the on-target effect.
• Stage-2 sleep elevation with evening dosing (Frieboes 1995, PMID 7617137).
• Modest ACTH and cortisol elevation — real, peer-reviewed (PMIDs 7617137, 9285939, 10336729). Not exceptional within the GHRP class — similar magnitude to GHRP-2 and hexarelin.
• Modest prolactin elevation — same caveat as cortisol.

Less-cited (community / vendor reports, low-PubMed-anchor):

• Water retention, mild fluid shifts (consistent with GH elevation).
• Injection-site redness or irritation.
• Tingling / numbness in hands (mild fluid shifts).
• Drowsiness with evening dosing (consistent with the stage-2 sleep effect).
• Joint stiffness with chronic use (consistent with GH elevation generally).
• Headache, especially in the first week.

Audit-critical framing: the “intense hunger” framing is well-supported by the literature. The “high cortisol / pronounced HPA activation vs other GHRPs” framing that circulates online is not well-supported — these effects exist for GHRP-6 but are similar in magnitude to GHRP-2 and hexarelin (PMID 9285939).

No Western pharmacovigilance database (FAERS, EudraVigilance, Yellow Card) entries because the molecule has never been approved.

• Pregnancy / breastfeeding — no safety data; avoid.
• Active or prior cancer — conservative position for any GH/IGF-axis stimulant. GH/IGF-1 elevation and tumor biology are connected enough to warrant caution.
• Active diabetic retinopathy — class concern for GH elevation (consistent with rhGH labeling).
• Adrenal insufficiency — the modest cortisol/ACTH elevation may be relevant. Discuss with prescriber if managing Addison’s or chronic glucocorticoid therapy.
• Acromegaly / pituitary tumor — absolute contraindication.
• Active eating disorder — the strong appetite signal can worsen restrictive or binge patterns.
• Athletes subject to anti-doping testing — do not use. WADA S2.2 lists GHRP-6 by name; banned at all times.
• Concurrent insulin or sulfonylureas — theoretical hypoglycemia risk via GH counter-regulatory effects; discuss with prescriber.

• Ghrelin (the natural hormone). Endogenous 28-residue acylated peptide secreted by gastric P/D1 cells. Same receptor as GHRP-6, structurally unrelated, requires octanoylation at Ser3 for binding. GHRP-6 is the synthetic small-peptide mimetic that predicted the existence of ghrelin.
• MK-677 (ibutamoren). Non-peptide, orally active GHS-R1a agonist (Patchett 1995, PMID 7624358). Same receptor as GHRP-6 but small-molecule, oral, ~24-hour half-life. Different molecule entirely.
• Hexarelin (examorelin). The position-2 D-Trp-methylated GHRP-6 cousin. Higher GH-releasing potency.
• Ipamorelin. Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Different scaffold, designed for GHS-R1a selectivity without HPA-axis activation. The cleanest comparator for “what GHRP-6 isn’t.”
• GHRP-2 (pralmorelin / KP-102). N-terminus-modified GHRP-6 derivative. Higher GH potency. Reached pharma development in Japan as a GH-deficiency diagnostic.
• [D-Lys³]-GHRP-6 (the antagonist). Same parent peptide with position-3 Ala swapped for D-Lys, converting the agonist into a competitive GHS-R1a antagonist. Used as a research tool, never therapeutically. If a vendor lists "D-Lys3-GHRP-6" as a product, that’s a different molecule with the opposite effect.